Online healthcare company Teladoc Health’s shares fell Thursday as several analysts lowered their share-price targets – following lower-than-expected quarterly earnings.
Teladoc reported a loss of -$1.31 a share, steeper than the -40 cents loss expected by analysts. It is also wider than the year-ago quarter’s -40 cents per share.
Evercore ISI’s Elizabeth Anderson slashed her price target to $185 from $195 and kept her in-line rating. While she viewed the membership forecast and lower guidance for EBITDA in the second half of 2021, on rising expenses as negatives, she saw tailwinds in the increased revenue outlook, including the combined sales pipeline and TDOC’s specialty and mental health traction.
Citi analyst Daniel Grosslight lowered his price target on Teladoc shares to $260 from $275, but maintained his buy rating. “By most metrics, TDOC’s quarter was solid,” he said, but added that Teladoc faces “greater competitive intensity.”
Cowen analyst Charles Rhyee cut his price target to $240 from $268, while keeping his outperform rating. According to Rhyee, earnings were strong, but investors expected more and were disappointed visit gains “didn’t flow through to revenue.”